On Thursday shares of NewLink Genetics Corporation (NASDAQ:NLNK) closed at $53.59. Company’s sales growth for last 5 years was 186.10%. Jefferies Group lowered shares of NewLink Genetics Corp (NASDAQ:NLNK) from a buy rating to a hold rating in a research report released on Thursday.
On last trading day General Electric Company (NYSE:GE) moved up 0.40% to close at $24.94. Its volatility for the week is 1.11% while volatility for the month is 1.37%. GE’s sales growth for past 5 years was -0.80% and its EPS growth for past 5 years was 8.80%. General Electric Company (NYSE:GE) monthly performance is -2.81%. General Electric Company (NYSE:GE) suspended home-appliance production for one week at its massive facility in Louisville, Ky., after a six-alarm fire destroyed a warehouse and generated thick clouds of dark smoke that prompted local officials to order nearby residents to stay indoors.
On Thursday shares of JA Solar Holdings Co., Ltd. (NASDAQ:JASO) closed at $9.67. Company’s sales growth for last 5 years was 5.60% and EPS growth for next 5 years is recorded as 22.00%. JA Solar Holdings Co., Ltd. (NASDAQ:JASO) on 2 April 2015, announced that Mr. Yong Liu, Chief Technology Officer, has resigned for personal reasons. Mr. Liu has also relinquished his position on the Board of Directors, effective March 31, 2015.
Masco Corporation (NYSE:MAS) in last trading activity moved up 2.11% to close at $26.62. Company weekly performance is 2.98% while its quarterly performance stands at 6.01%. Masco Corporation (NYSE:MAS) is -2.85% away from its 52 week high. Masco Corporation (NYSE:MAS) announced that its Board of Directors declared a quarterly dividend of $.09 per common share, payable on May 11, 2015, to shareholders of record on April 10, 2015.
On Thursday shares of Threshold Pharmaceuticals Inc. (NASDAQ:THLD) closed at $4.05. Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) announced it will present data on its investigational anti-cancer drugs at the annual meeting of the American Association for Cancer Research (AACR) 2015 being held April 18-22, 2015, in Philadelphia, Pennsylvania. The company will present clinical and preclinical data on TH-4000, its proprietary, hypoxia-activated irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).